問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Radiation Therapy

Division of Otolaryngology

Division of Hematology & Oncology

更新時間:2024-06-04

楊慕華Yang, Muh-Hwa
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 1 個月

篩選

List

115Cases

2025-10-01 - 2029-12-31

Active
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • Condition/Disease

    Squamous Cell Carcinoma of Head and Neck

  • Test Drug

    Injectable drugs Subcutaneous injections Injectable drugs Injectable drugs Injectable drugs

Participate Sites
7Sites

Recruiting7Sites

2025-11-01 - 2027-08-22

Phase II

Active
A phase 2, double-blind, placebo-controlled trial evaluating LY3537021 in adult participants with chemotherapy-induced nausea and vomiting due to malignant disease.
  • Condition/Disease

    Chemotherapy-induced nausea and vomiting

  • Test Drug

    LY3537021

Participate Sites
5Sites

Recruiting5Sites

2021-04-01 - 2033-02-28

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2018-03-16 - 2024-12-05

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated5Sites

2021-01-01 - 2025-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2020-11-25 - 2024-12-31

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2019-05-01 - 2025-12-31

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-10-01 - 2024-07-31

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting3Sites

Terminated3Sites

2021-09-01 - 2025-03-31

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2024-06-01 - 2028-10-22

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites